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Summary
Background Early cognitive intervention is the only routine therapeutic approach used for amelioration of intellectual 
deficits in individuals with Down’s syndrome, but its effects are limited. We hypothesised that administration of a 
green tea extract containing epigallocatechin-3-gallate (EGCG) would improve the effects of non-pharmacological 
cognitive rehabilitation in young adults with Down’s syndrome.
Methods We enrolled adults (aged 16–34 years) with Down’s syndrome from outpatient settings in Catalonia, Spain, with 
any of the Down’s syndrome genetic variations (trisomy 21, partial trisomy, mosaic, or translocation) in a double-blind, 
placebo-controlled, phase 2, single centre trial (TESDAD). Participants were randomly assigned at the IMIM-Hospital del 
Mar Medical Research Institute to receive EGCG (9 mg/kg per day) or placebo and cognitive training for 12 months. We 
followed up participants for 6 months after treatment discontinuation. We randomly assigned participants using random-
number tables and balanced allocation by sex and intellectual quotient. Participants, families, and researchers assessing 
the participants were masked to treatment allocation. The primary endpoint was cognitive improvement assessed by 
neuropsychologists with a battery of cognitive tests for episodic memory, executive function, and functional 
measurements. Analysis was on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number 
NCT01699711.
Findings The study was done between June 5, 2012, and June 6, 2014. 84 of 87 participants with Down’s syndrome 
were included in the intention-to-treat analysis at 12 months (43 in the EGCG and cognitive training group and 41 in 
the placebo and cognitive training group). Differences between the groups were not significant on 13 of 15 tests in the 
TESDAD battery and eight of nine adaptive skills in the Adaptive Behavior Assessment System II (ABAS-II). At 
12 months, participants treated with EGCG and cognitive training had significantly higher scores in visual recognition 
memory (Pattern Recognition Memory test immediate recall, adjusted mean difference: 6·23 percentage points 
[95% CI 0·31 to 12·14], p=0·039; d 0·4 [0·05 to 0·84]), inhibitory control (Cats and Dogs total score, adjusted mean 
difference: 0·48 [0·02 to 0·93], p=0·041; d 0·28 [0·19 to 0·74]; Cats and Dogs total response time, adjusted mean 
difference: –4·58 s [–8·54 to –0·62], p=0·024; d –0·27 [–0·72 to –0·20]), and adaptive behaviour (ABAS-II functional 
academics score, adjusted mean difference: 5·49 [2·13 to 8·86], p=0·002; d 0·39 [–0·06 to 0·84]). No differences were 
noted in adverse effects between the two treatment groups.
Interpretation EGCG and cognitive training for 12 months was significantly more effective than placebo and cognitive 
training at improving visual recognition memory, inhibitory control, and adaptive behaviour. Phase 3 trials with a 
larger population of individuals with Down’s syndrome will be needed to assess and confirm the long-term efficacy of 
EGCG and cognitive training.
Funding Jérôme Lejeune Foundation, Instituto de Salud Carlos III FEDER, MINECO, Generalitat de Catalunya.
Introduction
Down’s syndrome is the most common intellectual 
disability of genetic origin, affecting more than 5 million 
people worldwide. Medical interventions have 
substantially increased the life expectancy of individuals 
with Down’s syndrome in high-income countries, but 
cognitive and behavioural features have a strong effect 
on functional ability. No approved intervention exists for 
the amelioration of cognitive deficits in individuals with 
Down’s syndrome.1,2 Only early intervention programmes 
have resulted in some improvement in intellectual 
disability.3 Also, memory-training programmes have 
been reported to improve memory in adults with Down’s 
syndrome.4
Evidence suggests that flavonoid-rich foods (eg, green 
tea) can improve normal cognitive function and might 
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have therapeutic effects in Alzheimer’s disease because 
their biological actions include antioxidant effects; they 
also have the potential to protect susceptible neurons, 
enhance existing neuronal function, reduce toxic 
concentrations of amyloid (Aβ), and stimulate neuronal 
plasticity.1,5 Bain and colleagues6 described the non-
competitive inhibition properties of epigallocatechin-3-
gallate (EGCG), the major catechin in green tea leaves 
(40–50% of total catechins) on the kinase activity of the 
dual-specificity tyrosine-(Y)-phosphorylation-regulated 
kinase 1A (DYRK1A), a serine-threonine kinase encoded 
by the DYRK1A gene, located in the Down’s syndrome 
critical region (ie, on the long arm of chromosome 21) and 
thought to be a major contributor to cognitive phenotypes 
of Down’s syndrome. EGCG can cross the blood–brain 
barrier,7 and chronic administration of a green tea extract 
containing 45% EGCG promoted learning and memory in 
Down’s syndrome mouse models8 and was safe in young 
individuals with Down’s syndrome in our phase 1 trial.9 
Housing conditions that facilitate enhanced sensory, 
cognitive, motor, and social stimulation normalises 
DYRK1A kinase activity in the hippocampus of Down’s 
syndrome mouse models, suggesting that EGCG acts 
synergistically with cognitive stimulation.10 The long-term 
efficacy of cognitive training has not been conclusively 
shown in individuals with Down’s syndrome. In this 
phase 2 trial, we compared the effectiveness of cognitive 
training plus placebo with cognitive training plus EGCG 
in adults with Down’s syndrome.
Methods
Study design and participants
The TESDAD study was a randomised, double-blind, 
placebo-controlled, phase 2 trial in adults with Down’s 
syndrome, and was done at the Hospital del Mar Medical 
Research Institute of Barcelona (Spain).
The trial was approved by the local ethics committee 
(CEIC Parc de Salut Mar, EGCG/DYRK1A/DS/IMIM/1), 
and done according to the Declaration of Helsinki and 
Spanish guidelines and regulations for data privacy.
Eligible participants, whose parent or carer agreed to 
ensure administration of the medication and attendance 
at all visits, were enrolled from a large cohort of 
outpatients of the Catalan Down Syndrome Foundation 
(Barcelona, Spain). We planned to include adults aged 
18–30 years of both sexes with Down’s syndrome (genetic 
Research in context
Evidence before this study
We searched PubMed for reports published from Jan 1, 1995, to 
Dec 31, 2015 in English,  with the terms “Down syndrome”, 
“trisomy 21”, “supplements”, “drugs”, and “cognitive 
treatment” or “cognition therapy”. We included all randomised 
clinical trials of dietary supplements and drugs reporting any 
assessment of cognitive function in patients with Down’s 
syndrome. Apart from the pilot clinical trial by our study group 
in 2010, we identified six additional clinical trials with four 
different interventions: three with donepezil, one with folinic 
acid, vitamins, and minerals, one with memantine, and one 
with L-acetyl carnitine.
Added value of this study
Cognitive impairments associated with intellectual disability 
syndromes were believed to be intractable, but recent progress in 
our understanding of the mechanisms underlying the 
impairments associated with genetic syndromes, such as fragile 
X syndrome and tuberous sclerosis, has resulted in identification 
of potential treatment targets, which are being tested in clinical 
trials. It is increasingly argued that even complex syndromes 
such as Down’s syndrome are potentially treatable. Most 
therapies targeting cognition in Down’s syndrome are 
neurotransmitter based, and are more often used in treating 
Alzheimer’s disease, like acetylcholinesterase inhibitors 
(donezepil, rivastagmine, galantamine), GABAergic antagonists 
(eg, pentetrazol), and N-methyl-D-aspartate receptor 
antagonists (memantine). Additionally, other compounds such 
as vitamins, mineral supplements, piracetam, or growth 
hormone have been used with little or no success. None of the 
previous clinical trials had combined  pharmacological treatment 
with cognitive training and none of them showed significant 
improvement in cognition, adaptive functionality, or language 
performance. This is the first randomised controlled clinical trial 
using a dietary supplement (green tea extracts containing 
epigallocatechin-3-gallate [EGCG], a green tea catechin), 
combined with cognitive training. Our study shows a significant 
improvement in memory, executive function, and facilitated 
adaptive behaviour. A major strength of the trial is the inclusion 
of secondary outcome measures, such as neuroimaging and 
neurophysiology complementary explorations. Our findings 
suggest that the treatment had a measurable effect on 
biomarkers such as cholesterol and homocysteine. Additionally, 
neuroimaging showed increased functional connectivity and 
normalised cortical excitability. Furthermore, the treatment 
resulted in few side-effects.
Implications of all the available evidence
Our findings suggest the possibility of improving long-term 
outcomes in individuals with Down’s syndrome, and also open 
the way for clinical trials of other treatments in this population, 
such as more specific or more potent DYRK1A inhibitors (already 
in development), antioxidants, or lipid modulators. EGCG and 
cognitive training are easy-to-use, affordable, and widely 
accessable. This approach could lead to clinically validated 
interventions manageable at the primary care level. Effective 
treatments will have substantial implications for health services 
because even small clinical improvements in cognitive 
outcomes could lead to substantial reductions in lifetime care 
needs for individuals with intellectual disability syndromes.
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variations of trisomy 21, partial trisomy, mosaic, or 
translocation) but, because of difficulties in recruitment, 
we widened the age range for inclusion to 16–34 years. 
We included participants with a BMI between 18·5 kg/
m² and 29·9 kg/m².
Patients with neurological disease other than Down’s 
syndrome, relevant medical disease (ie, comorbid 
leukaemia or  high-flow congenital heart disease), 
comorbid unstable mental disorder, or taking any 
treatment that could interfere with cognitive function 
were excluded from the study. Other exclusion criteria 
were any major illness or major surgery in the past 
3 months before participation in the study; new or 
irregular medication in the month preceding the study; 
ingestion of vitamin or catechin supplements or non-
steroidal anti-inflammatory drugs in the 2 weeks before 
the study; gastrointestinal, hepatic, renal, or any other 
problems that might alter absorption, distribution, 
metabolism, or excretion of the drug. During the run-in 
period, participants had a brief cognitive assessment to 
estimate their intellectual disability based on the 
Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV).
Participants, parents, or their legal guardians were 
informed about the protocol and gave written informed 
consent.
Randomisation and masking
We randomly assigned participants to the EGCG and 
cognitive training group or the placebo and cognitive 
training group using random-number tables, and 
allocation was balanced by sex and intellectual quotient 
(IQ) (Kaufman Brief Intelligence Test [K-BIT; appendix] 
pXX). Individuals with an IQ of less than 40 were classified 
as having severe intellectual disability, whereas individuals 
with an IQ of 40–69 were classified as having moderate-to-
mild intellectual disability. This approach was taken to 
avoid bias in the inclusion of patients and an over-
representation of either IQ category in one of the 
treatments groups. Sequence generation, allocation 
concealment with a sealed opaque envelope, treatment 
allocation, and provision of labelled packs (both packs with 
identical appearance and size zero blue opaque capsules) 
were done by the Hospital del Mar Pharmacy Department. 
To ensure that the capsules were consumed, the 
participants’ carer or parent had to return the empty 
medication (EGCG or placebo) vials to the study 
coordinator (JR) before receiving a new vial. All members 
of the research team, the statistician, participants with 
Down’s syndrome, and their families or guardians were 
masked to treatment allocation. The double blind was 
maintained until the end of the follow-up.
Procedures
Before treatment, both groups had 1 month of a single-
blind placebo run-in period (participants and their 
families were masked). After the run-in period, 
participants received a green tea extract supplement 
containing 45% EGCG (Life Extension Decaffeinated 
Mega Green Tea Extract; Life Extension, Fort Lauderdale, 
FL, USA) or placebo (rice flour). Each capsule contained 
200 mg of EGCG or rice flour. Participants weighing 
50–75 kg were given three capsules (600 mg/day EGCG 
or placebo) and those weighing 75–100 kg were given 
four capsules (800 mg/day EGCG or placebo) orally for 
12 months, and had a follow-up visit 6 months after 
treatment discontinuation. All participants were to 
receive regular cognitive training sessions (30–50 min 
per session, 3 days per week) at home or at the offices of 
the Catalan Down Syndrome Foundation during the 
12 months of treatment. The run-in period was to 
familiarise participants with the cognitive training 
programme software (FesKits) and routine. FesKits 
enables participants to access a wide range of training 
programmes and exercises on the internet. Cognitive 
training focused on memory, executive functions, and 
language and attention processes; training on memory 
comprised 50% of the content of each training session. 
Training was adapted to learning progression and a 
neuropsychologist did a weekly follow-up to ensure 
compliance with the cognitive training sessions. During 
the run-in period, while receiving placebo, patients 
attended five sham cognitive training sessions.  After the 
run-in period, while also receiving medication in the 
double-blind phase, patients were recommended to 
perform three sessions per week during the 12 months of 
treatment.
At 6 months, an interim analysis was done to determine 
whether to continue based on adverse effects and early 
signs of efficacy.
Outcomes
The primary outcome was the change from baseline at 12 
months in cognitive and functional components of the 
TESDAD neuropsychology battery,11 which included 
measures of attention, psychomotor speed, memory, 
executive functions, language, adaptive behaviour, quality 
of life, quality of sleep, and neuropsychiatric symptoms 
(appendix pXX). Additionally, we screened for changes 
related to dementia onset with the Dementia 
Questionnaire for People with Intellectual Disabilities. 
The TESDAD battery was developed for testing cognitive 
performance and adaptive functionality in adults with 
Down’s syndrome and was adapted from our phase 1 trial 
of EGCG.9 All neuropsychological outcomes were 
assessed at baseline, and 3 months, 6 months, and 
12 months after treatment initiation, and 6 months after 
treatment discontinuation. Since a gold standard does not 
exist for the assessment of cognition in individuals with 
intellectual disability, including those with Down’s 
syndrome, we assessed the key cognitive and functional 
domains known to be impaired in patients with Down’s 
syndrome and hypothesised to have clinical sensitivity to 
EGCG. A detailed description of the complete 
neuropsychological battery is provided in the appendix 
See Online for appendix
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(pXX). Psychomotor speed was measured with the Motor 
Screening Test (MOT, CANTAB). Attention was assessed 
with simple reaction time and span capacity measures 
using the Simple Reaction Time task (SRT, CANTAB); 
and the Spatial Span forward recall (SSP, CANTAB) and 
the Digit Span forward recall from the Wechsler Adult 
Intelligence Scale-III (WAIS-III) were used to assess 
visual and verbal information, respectively. Measures of 
visual episodic memory and learning were obtained using 
the CANTAB Paired Associates Learning (PAL) and the 
Pattern Recognition Memory test (PRM, CANTAB), and 
verbal episodic memory using the Cued Recall Test 
(CRT). For executive functioning, we assessed fractioned 
components of verbal fluency, working memory, 
planning, mental flexibility, and inhibitory control. Verbal 
word fluency was measured with the semantic fluency 
word generation task (participants were asked to generate 
as many words as possible in 1 min belonging to the 
specified category of animals). Working memory for 
visual and verbal information was assessed with the SSP 
(CANTAB) backward recall and the Digit Span backward 
recall (WAIS-III), respectively. Planning capacity was 
measured with the Tower of London from Drexel 
University (ToLDx) and mental flexibility with the Weigl 
Color-Form Sort Test. The Cats and Dogs Test was used to 
assess response inhibition. Finally, measures of 
expressive and receptive language were obtained with the 
Boston Naming Test and the Token Test, respectively. 
Adult versions of the selected cognitive tests were used 
with the exception of four tests that were too complex for 
adults with intellectual disability: the CRT (verbal episodic 
memory), the Cats and Dogs Test (inhibitory control), the 
Weigl Color-Form Sort Test (mental flexibility), and the 
ToLDX (planning ability). The child’s versions of these 
tests were administered to avoid floor effects.
Everyday life functionality was assessed with 
questionnaires for the following domains: adaptive 
behaviour, quality of life, quality of sleep, and 
neuropsychiatric symptoms. Measures of adaptive 
behaviour were obtained with the adult version of the 
Adaptive Behavior Assessment System-Second Edition 
(ABAS-II). Quality of life was assessed with the parents’ 
and guardians’ version of the Kidscreen-27. Quality of 
sleep was assessed with the Pittsburgh Sleep Quality 
Index (PSQI) and neuropsychiatric symptoms were 
assessed with the Neuropsychiatric Inventory (NPI). 
We planned to monitor Aβ-40 and Aβ-42 peptides and 
their truncated forms as biomarkers of amyloidosis, 
related to Alzheimer’s disease. Measurements were 
taken at baseline and at 6 months. However, we had 
technical problems with the assay for plasma INNO-BIA 
Aβ forms (INNO-BIA; Fujirebio Europe, Gent, Belgium) 
and the results were consistent within but not among 
batches and therefore these measurements are not 
reported.
The secondary outcomes were the changes from 
baseline in the following biomarkers: plasma 
homocysteine and transthyretin concentrations (as 
measures of DYRK1A kinase activity); aspartate 
transaminase (AST) and alanine transaminase (ALT) 
concentrations (for safety); treatment compliance; and 
HDL, LDL, oxidised-LDL, total cholesterol, and 
triglycerides (to assess lipid oxidation).
We assessed adverse events, including serious adverse 
events, and vital signs, and did physical and neurological 
examinations, electrocardiogram (ECG), and standard 
laboratory assessments at each visit.
We also did exploratory analyses. We used functional 
MRI (fMRI) and transcranial magnetic stimulation (TMS) 
to measure the resting-state functional connectivity 
patterns with fMRI in a subsample of the participants due 
to financial constraints. Participants had three sessions of 
fMRI (at baseline, 6 months, and 12 months after 
treatment initiation). Our imaging approach was 
primarily based on whole-brain mapping of the degree of 
functional connectivity of each voxel with all other voxels 
as the sum of correlations above a given Pearson’s 
coefficient threshold. A subsequent region-of-interest 
mapping of functional connectivity was generated from 
the changes identified in the connectivity degree maps, 
using a seed-based approach12 (appendix pXX). Three 
representative functional connectivity maps were 
obtained for each participant with regions of interest 
(seeds) placed at peak between-group connectivity degree 
differences in the frontal cortex, Wernicke’s area, and 
cerebellum. Neurophysiological changes were assessed 
with paired pulse TMS. The TMS subsample included 
the same patients who had fMRI and were assessed at the 
same timepoints (baseline, 6 months, and 12 months 
after treatment initiation). Motor-evoked potentials 
(MEPs) were recorded from the right or left abductor 
pollicis brevis muscle. The resting motor threshold 
(RMT) was set at the lowest stimulator output intensity 
capable of inducing an MEP of at least 50 microvolts 
peak-to-peak amplitude in relaxed state abductor pollicis 
brevis muscle in at least five of ten consecutive trials. 
Intracortical inhibition and data were obtained at 
interstimulus intervals of 3 ms and 5 ms (ICI-3 and ICI-5) 
and intracortical facilitation at interstimulus intervals of 
10 ms and 15 ms (ICF-10 and ICF-15), with the 
conditioning stimulus set at an intensity of 80% of the 
RMT and the suprathreshold stimulus at 120% of the 
RMT. An average of ten trials was used to define the 
amplitudes of peak-to-peak MEPs. Other exploratory 
analyses were the assessment of stability or reversibility 
of changes at 18 months (6 months after discontinuation 
of interventions), and body composition (eg, weight, total 
fat mass, lean mass, total body water, BMI) with electrical 
impedance (TANITA-MC-180; Tanita Europe BV, 
Amsterdam, Netherlands).
The predefined rules for early termination of the study 
were serious adverse events or negative results at the 
intermediate assessment of the study (6 months after 
randomisation).
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Statistical analysis
Sample size calculation was based on the results of the 
memory tests in our pilot study.9 We estimated that 100 
individuals with Down’s syndrome would have to be 
recruited to ensure 85 participants, assuming 15% 
would discontinue. The size of the treatment difference 
was ten units with an SD of 18 units. To ensure a power 
of 0·85 using the t test and assuming a mean difference 
of 10 units after 12 months of treatment with an 
SD of 15, 42 participants were needed in each group. 
Participants excluded after the run-in period, before 
beginning treatment, were excluded from the analyses 
on the modified intention-to-treat population. The 
changes from baseline in scores on primary and 
secondary outcomes, including all tests scores and 
plasma biomarkers, were analysed using mixed models 
for repeated measures, and included treatment, time, 
treatment-by-time interaction, sex, and baseline scores 
as independent variables. The treatment-by-time 
interaction allowed examination of treatment 
differences over time, but was excluded whenever it 
was not significant. In these cases, the models assumed 
a constant treatment difference with respect to changes 
from baseline over time. Because missing data were 
generally less than 5%, no imputation of missing values 
was done. To analyse the differences between the two 
groups with respect to baseline after the washout period 
of 6 months, ANCOVA models were used for all test 
scores. These models used as outcome variables the 
changes from baseline to month 18 and included 
treatment as an independent variable adjusting for sex 
and baseline score. The measure of interest in all the 
fitted regression models was the adjusted mean 
difference between both treatments with respect to 
changes from baseline. Additionally, the standardised 
mean differences (Cohen’s d) between both treatments 
were calculated for the changes from baseline after 
12 months and 18 months. For the TMS assessments, 
because of the small subsample, the non-parametric 
Wilcoxon-Mann-Whitney test was used to study the 
differences between treatments with respect to baseline. 
These additional analyses did not account for sex and 
baseline score. The fit of the linear mixed models and 
the ANCOVA models was done with the statistical 
software package R (version 3.1.1). Statistical 
significance was set at 0·05. To protect against type II 
errors, no corrections were applied for multiple 
comparisons.
The trial is registered with ClinicalTrials.gov, number 
NCT01699711.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between June 5, 2012, and June 6, 2014, we randomly 
assigned 87 patients (98% of 89 initially contacted). Three 
individuals withdrew before treatment initiation; 84 were 
included in the intention-to-treat analysis (41 in the placebo 
and cognitive training group and 43 in the EGCG and 
cognitive training group; figure 1). Demographic, genetic, 
and IQ characteristics were similarly distributed in both 
groups (table 1).
During the run-in period, patients were trained by 
neuropsychologists on how to do the cognitive training, 
but did not receive routine cognitive training . The total 
number of cognitive training sessions was similar 
between training groups (mean 107·5 [SD 48·8] vs 98·7 
[46·2] sessions). Mean number of sessions per week was 
1·8 (SD 0·9) in the EGCG and cognitive training group 
and 2·0 (0·9) in the placebo and cognitive training 
group; therefore, the compliance with cognitive training 
was suboptimum in both treatment groups (ie, less than 
the three recommended sessions per week). Differences 
between the groups were not significant on 13 of 15 tests 
in the TESDAD battery and eight of nine adaptive skills 
in the ABAS-II (appendix p 13–15).
In the EGCG plus cognitive training group after the 
44 patients assigned to placebo plus 
  cognitive training group and had 
  placebo run-in for 1 month
41 patients in the placebo plus 
  cognitive training group
41 participants assessed at 12 months
 (intention-to-treat population)
3 excluded*
 2 side-effects perceived by family
 1 mental disorder
2 excluded at 6 months
 1 mental disorder
 1 admitted to hospital
1 excluded at 12 months
 1 mental disorder
43 patients assigned to EGCG plus 
  cognitive training group and had 
  placebo run-in for 1 month 
43 patients in the EGCG plus cognitive 
 training group
43 participants assessed at 12 months
  (intention-to-treat population)
1 excluded at 6 months 
 1 mental disorder
2 excluded at 12 months
 1 episode of aggression
 1 mental disorder
89 patients assessed for eligibility
87 patients randomly assigned
2 declined to participate
Figure 1: Trial profile
EGCG=epigallocatechin-3-gallate. fMRI=functional MRI. TMS=transcranial magnetic stimulation. *Withdrew 
before treatment in the placebo and cognitive training group and were not included in the intention-to-treat 
analysis.
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12 months of treatment, we found a higher preservation 
of memory and an improvement of executive functioning 
compared with the placebo plus cognitive training group 
(figure 2, appendix pXX). At 12 months, the EGCG and 
cognitive training group had a significantly lower 
decrease in the percentage of correct answers in the 
immediate visual memory recognition task with respect 
to baseline performance (PRM immediate recall; 
adjusted mean difference 6·23 percentage points 
[95% CI 0·31 to 12·14], p=0·039; d 0·4 [0·05 to 0·84]) and 
better scores and reduced total response time in the 
inhibition task (Cats and Dogs total correct, adjusted 
mean difference: 0·48 [95% CI 0·02 to 0·93], p=0·041; 
d 0·28 [0·19 to 0·74]; Cats and Dogs total response time, 
adjusted mean difference: –4·58 s [–8·54 to –0·62], 
p=0·024; d –0·27 [–0·72 to –0·20]) compared with the 
placebo and cognitive training group.
The EGCG and cognitive training group also showed 
improvement in adaptive behaviour in functional 
academic skills, as measured with the ABAS-II functional 
academics score (adjusted mean difference 5·49 [95% CI 
2·13 to 8·86], p=0·002; d 0·39 [–0·06 to 0·84]; figure 2, 
appendix pXX), but non-significant changes in social 
skills (ABAS social skills, adjusted mean difference: 2·56 
[–0·22 to 5·35], p=0·071; d 0·36 [–0·09 to 0·81]) compared 
with the placebo and cognitive training group. Concerning 
quality of life, we found no significant difference among 
the groups on the dimensions of social functioning and 
the relation with peers (Kidscreen-27 Social Support and 
Peers, adjusted mean difference: 3·25 [95% CI 
–0·37 to 6·88], p=0·078; d 0·63 [0·15 to 1·11]).
The safety and tolerability of EGCG were good. Adverse 
events were mainly mild and not thought to be related to 
the treatment, with no differences between the EGCG and 
placebo groups (table 2). There were no withdrawals 
related to drug tolerability. No significant differences were 
detected for changes in AST (p=0·831) and ALT (p=0·623; 
appendix p 12), nor were there alterations in ECG.
6 months after treatment discontinuation, the positive 
effects of EGCG and cognitive training on memory and 
executive functions persisted. The EGCG and cognitive 
training group had a higher memory performance in the 
immediate recall of verbal information in the list learning 
task (CRT free immediate recall, adjusted mean difference 
1·98 points [95% CI 0·23 to 3·74], p=0·027; d 0·41 
[–0·05 to 0·87]). Also, a greater accuracy and response 
speed was detected in the EGCG and cognitive training 
group in the response inhibition task (Cats and Dogs total 
correct score, adjusted mean difference: 0·51 [95% CI 
0·09 to 0·93], p=0·017; d 0·46 [0·01 to 0·92]; Cats and 
Dogs total response time: –5·21 s [–8·5 to –1·92], p=0·002; 
d –0·6 [–1·07 to –0·12]). The positive effect on adaptive 
behaviour on basic health care and safety skills (ABAS-II 
health and safety, adjusted mean difference: 2·9 [95% CI 
–0·25 to 6·05], p=0·071; d 0·41 [0·03 to 0·85]) in the group 
receiving EGCG and cognitive training was not significant 
(appendix pXX). The positive effects on ABAS-II 
Figure 2: Effects of EGCG and cognitive training or placebo and cognitive training on neurocognitive 
performance and adaptive behaviour
Effects of EGCG and cognitive training versus placebo and cognitive training over time as assessed by the Cats and 
Dogs inhibition task, total time (A) and total score (B), the Pattern Recognition Memory (PRM) test, percent 
immediate recall (C), and adaptive behaviour in the Adaptive Behavior Assessment System II (ABAS-II) functional 
academics total score (D). EGCG=epigallocatechin-3-gallate.
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Sex
Male 21 (48%) 24 (56%)
Female 23 (52%) 19 (44%)
Age (years) 23·4 (4·9) 23·1 (3·6)
Trisomy
Simple 43 (98%) 40 (93%)
Translocation 0 2 (5%)
Mosaicism 1 (2%) 0 
Partial trisomy 0 1 (2%)
Body-mass index 
(kg/m²)
25·9 (4·3) 25·6 (4·2)
Intelligence quotient
<40 18 (41%) 18 (42%)
40–69 26 (59%) 25 (58%)
Data are number (%) or mean (SD). EGCG=epigallocatechin-3-gallate. 
Table 1: Baseline demographic and clinical characteristics
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functional academics score also faded after discontinuing 
the treatment (adjusted mean difference: 3·22 [95% CI 
–1·44 to 7·88], p=0·172). Finally, we did not find significant 
effects on overall quality of life (Kidscreen-27 total score, 
adjusted mean difference: 10·09 [95% CI –5·86 to 26·04], 
p=0·21).
Ten individuals in the EGCG and cognitive training 
group and ten in the placebo and cognitive training 
group had valid fMRI assessments at baseline. Eight 
patients in the placebo and cognitive training group and 
ten in the EGCG and cognitive training group had valid 
fMRI assessments both at baseline and 6 months after 
initiating treatment; and two of ten patients were 
excluded from the EGCG and cognitive training group 
because of motion artefacts. Nine patients in the placebo 
and cognitive training group and nine in the EGCG and 
cognitive training group had valid fMRI assessments 
both at baseline and 12 months; and one patient was 
excluded from each group because of motion artefacts. 
Thus, we report the results for 6 months and 12 months 
separately (appendix p 20, 21). fMRI session (baseline vs 
6 months) by treatment interaction of the functional 
connectivity degree analysis, showed a significant 
interaction in the frontal cortex (t score=4·2), Wernicke 
area (t score=3·1), cerebellum (t score=4·2; appendix 
pXX), and in a subcortical cluster partly involving a 
number of regions (appendix pXX). A post-hoc paired 
t test showed that most of the effect was due to an 
increase in connectivity associated with the EGCG and 
cognitive training group (appendix p 19). For the seed-
based functional connectivity analysis, three different 
functional connectivity maps were generated using the 
areas that had significant effects in the connectivity 
degree analysis as the seed regions of interest. In the 
frontal cortex seed map, session-by-treatment interaction 
showed a significant increase in connectivity in the 
frontal (t score=4·7), somatosensory (t score=4·2), and 
occipito-temporal cortices (t score=4·7; appendix p 17). 
In the Wernicke seed map, we noted a significant 
interaction in the posterior cingulate cortex and the 
precuneus (t score=4·0). In the cerebellar seed map, 
significant interactions were noted within the cerebellum 
(t score=5·0; appendix p 17). After 12 months of 
treatment, we recorded changes (baseline vs 12 months) 
in the same areas identified at 6 months, suggesting a 
persistent effect of EGCG and cognitive training 
(appendix pXX). However, the changes were only 
significant in the frontal cortex (appendix pXX).
The placebo and cognitive training group and the 
EGCG and cognitive training group had slightly different 
ICF-15 baseline values, with the facilitation values in the 
placebo and cognitive training group being closer to 
normal than in the EGCG and cognitive training group 
(normal mean baseline ICF-15 value 1·22 [SD 0·40], 
placebo and cognitive training 2·72 [2·36], EGCG and 
cognitive training 3·28 [2·19]). At 6 months, the placebo 
and cognitive training group fared significantly better 
than the EGCG and cognitive training group (mean ICF-
15 2·31 [SD 1·61] vs 3·47 [3·69], p=0·015), although the 
median changes from baseline were not significant 
(–0·41 [IQR 1·12] vs 0·18 [2·72]). At 12 months of 
treatment, the increased facilitation was significantly 
abated in the group receiving EGCG and cognitive 
training compared with the placebo and cognitive 
training group (mean ICF-15 2·01 [1·43] vs 3·61 [5·81], 
p<0·0001; median change from baseline –1·28 [IQR 
1·58] vs 0·89 [2·10], p<0·0001). No significant differences 
were detected for ICI-3 (p=0·67), ICI-5 (p=0·67), or ICF-
10 (p=0·56; appendix p 23).
In the EGCG and cognitive training group at 12 months, 
we noted significant changes from baseline in total 
cholesterol (adjusted mean difference –8·91 [95% CI 
–16·3 to –1·51], p=0·019; figure 3), oxidised LDL (adjusted 
mean difference –3·7 [–6·93 to –0·44], p=0·027) and HDL 
(adjusted mean difference –4·06 [–7·39 to –0·72], p=0·011) 
plasma concentrations, that were reduced in the EGCG 
and cognitive training group compared with the placebo 
and cognitive training group (appendix p 11). No 
significant differences were detected for LDL (p=0·072) 
and triglycerides (p=0·178; appendix p 11).
We also recorded significant increases from baseline in 
total plasma homocysteine in the group receiving EGCG 
and cognitive training compared with the placebo and 
cognitive training group after the 12 months of intervention 
(adjusted mean difference 0·7 [95% CI 0·14 to 1·26], 
p=0·015; figure 3). The differences in homocysteine 
plasma concentrations disappeared after discontinuing 
treatment with EGCG (adjusted mean difference 0·15 
[95% CI –0·64 to 0·93], p=0·71). Transthyretin results are 
shown in the appendix (p 11).
After 12 months of treatment, our analyses did not show 
significant weight loss or change in body-mass index 
(BMI) (appendix  p 11). At 18 months, 6 months after 
Figure 3: Treatment effects of EGCG and cognitive training versus placebo and cognitive training on total 
cholesterol and total homocysteine plasma concentrations
(A) Treatment effects of EGCG and cognitive training on total cholesterol were significant at 12 months (p=0·019) 
but were no longer significant after discontinuing EGCG at 18 months (p=0·506). (B) Treatment effects of EGCG 
and cognitive training on total homocysteine were significant at 12 months (p=0·015) but were no longer 
significant after discontinuing EGCG at 18 months (p=0·71). EGCG=epigallocatechin-3-gallate.
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treatment discontinuation, differences in weight loss 
between EGCG plus cognitive training and placebo plus 
cognitive training groups increased (1·48 kg) and were 
significant (p=0·044), the mean difference from baseline 
being –0·16 kg in the EGCG and cognitive training group 
versus 1·32 kg in the placebo and cognitive training group 
with similar differences in BMI (p=0·037; appendix p 11).
Discussion
Our study showed that patients in the EGCG plus 
cognitive training group performed better than those in 
the placebo plus cognitive training group in some 
cognitive tests and in adaptive behaviour after the 
12 months of treatment (appendix pXX). The EGCG and 
cognitive training group had better preservation of 
recognition memory tasks and improvement in executive 
function than the placebo and cognitive training group. 
Improvements in memory and executive function were 
accompanied by improved performance of daily tasks 
requiring basic literacy in the EGCG and cognitive 
training group. Benefits in functional academics imply 
an improvement in the use of basic literacy skills 
(reading, writing, and mathematics), allowing daily 
independent functioning (ie, recognise the time, be able 
to read and write small notes, recognise small quantities 
when paying, and performing small operations). 
Sustained effects of EGCG were observed after 18 months 
in memory and executive function. Even though the 
effects of EGCG and cognitive training on cognitive 
function were small and of subclinical magnitude, they 
were accompanied by a positive functional change on 
adaptive behaviour, with an absence of relevant negative 
side-effects. Safety monitoring showed no adverse effects 
associated with EGCG and cognitive training. The 
benefits seem thus substantial, given the fairly short 
treatment (1 year).
The improvement in memory and executive function 
deficits with EGCG and cognitive training were similar 
to the results of our previous phase 1 clinical trial9 using 
EGCG without cognitive training. In both trials, the 
main effect of EGCG was the improvement of immediate 
recognition memory. This measure is sensitive to 
hippocampal and, in particular, perirhinal cortex activity, 
in addition to regions such as ventromedial cortices.14 In 
Down’s syndrome, altered functionality of the 
hippocampus and prefrontal cortex contributes to 
memory and executive functioning deficits15,16 and, in a 
previous neuroimaging study,12 we identified distinct 
connectivity disturbances in frontal and anterior 
temporal structures.
Our study was not powered to assess the effect of the 
treatment on each component of the secondary outcomes. 
Nonetheless, EGCG and cognitive training was superior 
to placebo in two secondary outcome components, with a 
significant increase in connectivity in the frontal, 
somatosensory, and occipito-temporal cortices, and 
cortical excitability normalisation. Resting-state fMRI 
measurements showed a marked enhancement of 
regional functional connectivity with increases in the 
functional integration of cortical and subcortical 
distributed networks, including the frontal cortex, 
Wernicke area, the precuneus, occipito-temporal and 
somatosensory cortices, and basal ganglia in the EGCG 
and cognitive training group. Treatment-related changes 
in functional connectivity within frontal networks were 
significantly correlated with the increase in ABAS-II 
functional academic skills. Using non-invasive TMS,17–19 
we showed that EGCG and cognitive training normalised 
intracortical facilitation. We speculate that these effects 
could also contribute to the improved cognitive abilities in 
individuals treated with EGCG and cognitive training, 
since cognitive deficits in Down’s syndrome have been 
proposed to result from an imbalance, with an excess of 
synaptic inhibition in the hippocampus and increased 
excitation in the cerebral cortex.18,20
In previous studies,8,9 the efficacy of EGCG was 
suggested to depend, at least partly, on the ability of EGCG 
to inhibit DYRK1A kinase activity, a major candidate for 
Down’s syndrome cognitive and neural plasticity 
phenotypes.1,2 Total homocysteine plasma concentrations, 
used as a surrogate biomarker of DYRK1A kinase 
activity,21,22 were increased to amounts that were not in the 
cardiovascular risk range in the EGCG and cognitive 
training group but not in the placebo and cognitive 
training group, and returned to baseline concentrations 
after treatment discontinuation. However, we did not 
control for other factors such as vitamin B12 or folate that 
could also contribute to increased homocysteine plasma 
concentrations. In this study, we also noted a reduction in 
total cholesterol and oxidised LDL concentrations. Thus, a 
Placebo and 
cognitive 
training (n=43)
EGCG and 
cognitive 
training (n=41)
Serious adverse events 
Mental disorder 1 (2%) 2 (5%)
Admission to hospital 1 (2%) 1 (2%)
Non-serious adverse events 
Upper respiratory tract infection 21 (42%) 18 (42%)
Osteoarticular pain 5 (10%) 6 (14%)
Headache 1 (2%) 3 (7%)
Menstrual disturbances 3 (6%) 3 (7%)
Mood disorders 5 (10%) 3 (7%)
Abdominal pain 5 (10%) 2 (5%)
Skin infections 4 (8%) 1 (2%)
Asthenia 0 2 (5%)
Celiac disease diagnosis 0 2 (5%)
Gastrointestinal infections 2 (4%) 0
Tremors and dizziness 2 (4%) 0
Values are n (%).
Table 2: Adverse events by treatment group occurring in more than two 
participants
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lipid-lowering effect combined with a reduced lipid 
oxidation might contribute to the therapeutic effect. 
However, other mechanisms of action of EGCG should 
not be disregarded, including epigenetic,23 mitochondrial 
dysfunction rescue,24 antioxidant, and hypolipidaemic 
effects.25
Markers of cardiac and hepatic toxicity were endpoints 
of particular interest. In-vitro studies have shown that 
EGCG is a low-affinity inhibitor of hERG,26 but in-vivo 
studies in dogs could not relate these effects to cardiac 
toxicity.27 Nevertheless, cardiac toxicity at high doses 
cannot be excluded and caution should be taken when 
EGCG is given concurrently with cardiovascular drugs. 
In our study, we did not see alterations in ECG during 
EGCG treatment. Markers of hepatotoxicity were 
unaltered throughout the study. The pharmacokinetics 
and metabolic disposition of EGCG have been reported;28 
clinical studies with EGCG in multiple sclerosis at doses 
in the range of those tested in the present study and for 
similar periods of exposure showed that EGCG plasma 
concentrations were associated with changes in brain 
N-acetyl aspartate, an EGCG metabolite.29
The study had some limitations. First, for technical 
reasons we could not measure amyloidosis biomarkers. 
We do not believe this limitation compromises the 
conclusions of our study because our population was 
within an age range in which neurodegeneration due to 
Alzheimer’s disease is unlikely, and we monitored 
clinical signs with specific questionnaires like the 
Dementia Questionnaire for Persons with Mental 
Retardation. Second, although our study had a long 
follow-up, phase 3 trials with a larger population of 
individuals with Down’s syndrome will be needed to 
assess and confirm the long-term efficacy of EGCG and 
cognitive training. We do not expect serious side-effects 
if the EGCG dose is maintained at fairly low 
concentrations such as those used in our study. Third, 
due to the large number of tests done in the framework 
of the regression models, the family-wise error rate 
exceeded 0·05. Nonetheless, to protect against type II 
errors, no corrections for multiple comparisons were 
applied. Otherwise, with a family-wise error rate of 0·05, 
the significance of each test would have been restrictive. 
No significant positive cognitive or functional effects 
were detected in the placebo group. To rule out the 
possibility that any of the significant results was a type I 
error, further studies are needed. Fourth, we are aware 
that the choice of our assessment instruments might 
have restricted the detection of EGCG effects. Therefore, 
this battery will undergo future modifications to integrate 
the feedback from the TESDAD study, future clinical 
trials, and any clinical or preclinical evidence. 
Nevertheless, the state of the field in testing for cognitive 
changes is not yet appropriately developed and findings 
from our clinical trial cannot be validated against a 
consensus gold standard. This is an important caveat 
that should be considered when interpreting the results 
of this study. Finally, although it is not possible to 
compare EGCG with other treatments, we expect to see 
more developments in this area of research, especially in 
multicomponent therapies. However, it should be noted 
that the long-term efficacy of cognitive training has not 
been conclusively shown in people with Down’s 
syndrome across all studies.
We conclude that EGCG with cognitive training had 
beneficial effects on memory and executive deficits with 
enhancement of the everyday life competence in young 
adults with Down’s syndrome, although some domains 
were not significantly modified by the treatment. The 
combined intervention of EGCG and cognitive training 
for 12 months seem to ameliorate functional integration 
of cortical and subcortical brain networks in this 
population. Although other statistically underpowered 
studies have reported preliminary data suggesting that 
cognitive and adaptive skills in Down’s syndrome might 
be treated through pharmacological intervention,9,30 this 
study is the first well-powered trial that shows 
improvement in adaptive behaviour (functional 
academics) and brain-related changes in young adults 
with Down’s syndrome. However, more research is 
needed to clarify the nature of the beneficial association 
between the EGCG and cognitive training intervention 
(ie, synergistic or additive). Although efficacy combined 
with a good safety profile supports the use of this 
treatment in clinics, more phase 2 and 3 clinical trials are 
warranted to further support the use of this catechin for 
improvement of cognitive function in Down’s syndrome.
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